Regentis Biomaterials Ltd (RGNT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-1999 | 12-1998 | 12-1997 | 12-1996 | |
| Assets | ||||
| Current Assets | ||||
| Other current assets | 3,830 | 280 | 240 | 100 |
| TOTAL | $3,830 | $280 | $240 | $100 |
| Non-Current Assets | ||||
| Investments And Advances | 380 | 260 | 400 | 260 |
| Other Non-Current Assets | 5,900 | 11,570 | 4,000 | 2,230 |
| TOTAL | $6,280 | $11,830 | $4,400 | $2,490 |
| Total Assets | $10,110 | $12,110 | $4,640 | $2,590 |
| Liabilities | ||||
| Current Liabilities | ||||
| Short Term Debt | 2,260 | 280 | 210 | 140 |
| Accounts payable and accrued liabilities | 3,410 | 0 | 0 | 0 |
| Accrued Expenses | 1,920 | 1,530 | 680 | 390 |
| Other current liabilities | 460 | N/A | N/A | N/A |
| TOTAL | $8,050 | $1,810 | $5,390 | $530 |
| Non-Current Liabilities | ||||
| Other Non-Current Liabilities | 20,580 | 10,580 | 510 | 470 |
| TOTAL | $27,290 | $10,580 | $510 | $470 |
| Total Liabilities | $35,340 | $12,390 | $5,900 | $1,000 |
| Shareholders' Equity | ||||
| Common Shares | 10,610 | 10,800 | 10,800 | 10,800 |
| TOTAL | $10,610 | $10,800 | $10,800 | $10,800 |
| Total Liabilities And Equity | $45,950 | $23,190 | $16,700 | $11,800 |